Hexahydrocannabiphorol

Hexahydrocannabiphorol (HHCP, sometimes mistakenly referred to as hexahydroxycannabiphorol) is a semi-synthetic cannabinoid derivative which has been marketed since around 2021. It is believed to be made from the hydrogenation of tetrahydrocannabiphorol (THCP). THCP is only reported as a trace component of cannabis in 2019. HHCP was studied by Roger Adams as early as 1942.

Pharmacology
HHC-P is a partial agonist of the CB1 receptors with an EC50 of 44.4nM for 9R-HHCP and 134nM for 9S-HHCP. Compared to Hexahydrocannabinol (HHC) with an EC50 of 101nM for 9R-HHC and 1,190nM for 9S-HHC In 2021, HHC-P was positively identified in multiple retail electronic vaping products in the United States.

Legality
The legal status of hexahydrocannabinol and derivatives varies between countries, leading to widespread sale in some jurisdictions in Europe and the US.

In France, HHCP was banned in 2023.

In Japan, Japanese Health Ministry announced that six synthetic cannabinoids with structures similar to HHCH, including HHCP, were to be banned from 6 January 2024

HHCP was banned in Slovakia as of 13 January 2024.